摘要
目的比较聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)和重组人粒细胞集落刺激因子(rhG-CSF)预防化疗后中性粒细胞减少症的有效性和安全性。方法采用随机自身交叉对照,纳入42例初治恶性肿瘤患者,接受2个周期相同方案的化疗,其中试验周期给予PEG-rhG-CSF 100μg/kg皮下注射1次,对照周期皮下注射rhG-CSF5μg/(kg.d)直至外周血中性粒细胞绝对值(ANC)达低谷后连续2次检查≥5.0×109/L。结果 42例患者,在40个试验周期和44个对照周期中,ANC<2.0×109/L的发生率试验组和对照组分别为30%(12/40)和31.8%(14/44),持续时间分别为(3±1.155)d和(4±1.225)d;受试药和对照药的不良反应均主要为骨骼肌肉疼痛、乏力、发热、头晕等,发生率与严重程度相似。结论 PEG-rhG-CSF一次给药的疗效与与rhG-CSF多次给药相似,不良反应低。
Objective To compare the efficacy and safety of daily injection of recombinant human granulocyte colonystimulating factor (rbG-CSF) and a single subcutaneous injection of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in chemotherapy-induced neutropenia. Methods In the present randomized, match and cross-over study, enrolled 42 patients with previously untreated cancer and with normal bone marrow function were randomly divided into 2 matched groups. Each patient received two cycles of chemotherapy of identical regimen. In tile study cycle, the patients received a single subcutaneous injection of PEG-rhG-CSF 100μg/kg; and in control cycle, daily subcutaneous infection of rhG-CSF 5 μg/kg/d and continued for 7 days or until the absolute neutrophil count (ANC) became ≥5.0 × 10 9/L. Results The rates of ANC 〈 2. 0 × 10 9/L in the 40 evaluable study cycles and 44 evaluable control cycles were 30.00% and 31.8% with the duration of (3 ± 1. 155 )d and (4 ± 1. 225 )d respectively. The safety profiles of the PEG-rhG-CSF and rhG-CSF groups were similar. Conclusion A single subcutaneous injection of PEG-rhG-CSF 100μg/kg provides neutrophil support and a safety profile comparable to regimen of daily subcutaneous injection of rhG-CSF 5 μg/(kg· d) in patients receiving a variety of myelosuppressive chemotherapy regimens
出处
《四川医学》
CAS
2011年第12期1879-1882,共4页
Sichuan Medical Journal